Auscandoc<p>Long-Term Effectiveness Associated With Fecal Immunochemical Testing for Early-Age Screening | <a href="https://med-mastodon.com/tags/CancerScreening" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>CancerScreening</span></a>, Prevention, Control | JAMA Oncology | JAMA Network <a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2835051" rel="nofollow noopener" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">jamanetwork.com/journals/jamao</span><span class="invisible">ncology/fullarticle/2835051</span></a> “In this cohort study including 263 125, fecal immunochemical test (<a href="https://med-mastodon.com/tags/FIT" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>FIT</span></a>) screening initiated at age 40 to 49 years followed by screening after age 50 years was associated with a 39% and 21% reduction in CRC mortality and incidence, respectively, compared with starting screening at age 50 years”</p>